A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback